Wedbush Reaffirms “Neutral” Rating for SpringWorks Therapeutics (NASDAQ:SWTX)
SpringWorks Therapeutics (NASDAQ:SWTX – Get Free Report)‘s stock had its “neutral” rating reissued by equities researchers at Wedbush in a report released on Monday, Marketbeat.com reports. They presently have a $47.00 price objective on the stock, down from their prior price objective of $81.00. Wedbush’s price objective would indicate a potential upside of 1.64% from […]
SpringWorks Therapeutics (NASDAQ:SWTX – Get Free Report)‘s stock had its “neutral” rating reissued by equities researchers at Wedbush in a report released on Monday, Marketbeat.com reports. They presently have a $47.00 price objective on the stock, down from their prior price objective of $81.00. Wedbush’s price objective would indicate a potential upside of 1.64% from […]
